DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders

DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company
primarily focused on the development of novel, first-in-class therapies for
metabolic disorders, kidney dysfunction and orphan diseases, today announced
that at its Annual General and Special Meeting (the "Meeting") of shareholders
held on July 24, 2014, Michael Giuffre, Rick Pauls, Richard Pilnik, Dawson
Reimer and Thomas Wellner were re-elected as the Company's board of directors.


In addition to the election of directors, the shareholders passed all
resolutions placed before the Meeting as outlined in the management information
circular (the "Circular") dated June 26, 2014. As more particularly described in
the Circular, the additional resolutions included re-appointing KPMG LLP as
auditors for the upcoming year; approving the continuance of the Company under
the Canada Business Corporations Act; authorizing the Company's board of
directors to amend the Articles of Incorporation to consolidate the outstanding
common shares on the basis of one post-consolidation common share for each two
to ten pre-consolidation common shares; approving certain amendments to the
Company's by-laws; and renewing the shareholder rights plan of the Company.


About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company primarily focused on the development of novel,
first-in-class therapies for metabolic disorders, kidney dysfunction and orphan
diseases. DiaMedica's lead clinical stage product, DM199, recombinant human
tissue kallikrein-1 protein ("rhKLK-1"), is a novel, first-in-class, therapeutic
for the treatment of diabetes mellitus and associated complications. DiaMedica
also is developing DM204, a monoclonal antibody program, for glucose control and
cardiovascular complications in type 2 diabetes and a companion diagnostic in
vitro assay, DMDx, utilizing the detection of tissue kallikrein-1 protein
("KLK-1") as a potential biomarker in human urine to identify diabetic kidney
disease patients who are most likely to respond to a therapeutic regimen that
includes DM199. 


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS 

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, including the intended use of the net proceeds of the Offering,
should be considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions made by and
information currently available to management. When used in this document, the
words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and
words of similar import, are intended to identify any forward-looking
statements. You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future events and are
subject to certain risks and uncertainties as contained in DiaMedica's filings
with Canadian securities regulatory authorities. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those anticipated in
these forward-looking statements. DiaMedica undertakes no obligation, and does
not intend, to update, revise or otherwise publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof, or to reflect the occurrence of any unanticipated events, unless
required by law. Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these expectations will
materialize.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of the contents of this press
release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
John Savage
Chief Financial Officer
763-270-0603


DiaMedica Inc.
One Carlson Parkway, Suite 124
Minneapolis, MN
[e-mail]